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Survivin which is a member of inhibitor of apoptosis (IAP) family 
of proteins is known to play a key role in cell division and in apoptosis. 
It is found mainly in G2/M phase and very low in G0/G1 and S phase 
of the cell cycle [1]. Survivin has been found to be highly upregulated 
specifically in most cancer forms and absent in normal tissues, thus it 
serves as an important biomarker for tumour diagnosis and treatment 
[2,3]. Survivin modulates cell signalling pathways involving Wnt/β-
catenin, STAT3, TNFR, P13K/AKT, mTOR, HIF-1α, NF-κb, Erb-2, 
HSP90 and SPS thus having a key regulatory role in tumour progression 
[4]. It has been reported that survivin knockdown in tumour cells 
led to cell cycle arrest and apoptosis in tumour cells [5]. Survivin 
expression in cancer cells is not only related to cancer progression but 
it has also been reported that survivin expression co-relates with the 
drug resistance in B-cell lymphoma and treatments leading to survivin 
downregulation showed increased drug sensitivity in these cells. Thus, 
elevated levels of survivin expression have been correlated with drug 
resistance in cancer cells [6]. Studies have reported that viral infection 
also promotes survivin expression and increases the possibility of 
cancer. The latent membrane protein 1 (LMP1) of Epstein-barr virus 
(EBV) leads to an increase in P53 mediated survivin promoters activity 
and overexpression of survivin which can lead to nasopharyngeal 
carcinoma (NPC) [7]. The merkel cell polyomavirus (MCV) large T 
antigen interacts with the retinoblastoma protein (Rb) which is the cell 
cycle regulator protein and leads to overexpression of survivin that is 
responsible for 80% of all merkel cell carcinoma (MCC), a form of skin 
cancer [8]. The varicella-zoster virus that causes chicken pox triggers 
the signal transducers and activators of transcription 3 (STAT3) 
phosphorylation in cells which further induces survivin overexpression 
and may lead to development of cancer [9]. Role of survivin has also 
been explored in immune response and it was reported that the T cell 
cultures showed a decreased T cell proliferation and reduced cytotoxic 
T cell response post treatment with survivin. The reason behind this is 
that survivin induces a shift in the T cell response from type 1 to type 2 
response with decrease in the cytotoxic T cell functioning [10]. 
Many therapies have been developed for survivin targeting in 
order to treat various forms of cancer. Survivin antagonists have been 
highly successful against established tumours as they have proven to 
downregulate survivin expression and induce apoptosis in cancer cells 
[11]. The advantage of using the dominant negative mutant is that they 
do not harm the normal body cells and target only the cancer cells [12]. 
Gene therapy against survivin also proved to be highly successful in 
mouse model of EL-4 thymic lymphoma cells [13]. The most recent 
targeting methodology is use of locked nucleic acids (LNA) modified 
aptamers, mRNA sequences and antisense-oligonucleotides which have 
much higher target specificity and have been more successful than other 
forms of targeting methods. The introduction of aptamers and LNA has 
brought a revolutionary change in the modern approach of targeting 
and diagnostics. Aptamers are ss DNA or RNA oligonucleotides which 
have the ability to fold into unique 3 dimensional (3D) confirmations. 
These molecular ligands are highly selective and specific towards their 
targets and have a potential to inhibit target proteins in a broad range 
of disease [14]. LNA are a new class of high affinity cyclic analogs of 
nucleic acids in which the furanose ring of ribose sugar is chemically 
locked in an RNA mimicking conformation by introduction of the 2’-O, 
4’-C-methylene bridge and the conjugation of LNA with nanoparticles 
is known as locked nucleic acid nanoparticle conjugates of LNP’s [15]. 
LY2181308 [16], YM155 [17], SPC3042 [18] and EZN-3042 [19] are 
some of the antisense molecules which have been used as survivin 
inhibitors. The cytotoxic and apoptotic effects of LNA modified siRNA 
to survivin encapsulated in chitosan coated ceramic anti-cancer 
nanocarriers has been reported. It was observed that these nanocarriers 
were effective in inducing apoptosis and cytotoxicity specifically to 
the colon cancer cells (Caco-2) whereas no significant cytotoxicity 
or apoptosis was observed in the normal intestinal cells (FHS). The 
in vivo bio distribution study of these nanocarriers disclosed that the 
maximum number of nanocarriers internalized in the tumour, liver, 
brain and intestine apart from low accumulation in spleen, kidney, lung 
and heart. Once these nanocarriers were targeted using LNA-modified 
epithelial cell adhesion molecule (EpCAM) aptamer a ligand against 
surface molecule highly expressed by cancer cells, the accumulation in 
tumour was nearly 9 fold higher when compared to other organs. Thus 
the aptamer based survivin inhibitors were effectively able to target and 
inhibit colon cancer cells both in vitro and in vivo [20]. The significance 
of survivin as a biomarker for cancer is evident and due to its specific 
overexpression in cancer cells it has become an important anti-cancer 
therapeutic target. Survivin targeting has been accomplished by use of 
antibodies, antisense peptides, carrier peptides, aptamers, antisense 
oligonucleotides and nanoparticles but none of the therapies have been 
as successful as the antisense LNA therapy against survivin. Two such 
forms of treatments have made it to the clinical trials and have proved 
to be very promising as the future medicine for treatment of cancer.
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